ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0064

Correlation of Anti-DFS70 Autoantibodies by ELISA with HEp-2 Cells DFS Pattern by IFA

Vincent ricchiuti1, Michael Nappi2, Kelly Chun2, Ajay Grover1 and Rubio Punzalan2, 1Labcorp, Dublin, OH, 2Labcorp, Calabasas, CA

Meeting: ACR Convergence 2023

Keywords: Apoptosis, Autoantibody(ies), autoimmune diseases, Autoinflammatory diseases, Biomarkers

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 12, 2023

Title: (0040–0064) Innate Immunity Poster

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: The discovery and characterization of the dense fine speckled (DFS, ICAP AC-2) nuclear pattern of antinuclear autoantibodies (ANA) detected in HEp-2 cells by indirect immunofluorescence assay (IFA) more than 20 years ago has transformed our view on ANA testing. Anti-DFS70 antibodies are associated with this DFS pattern by IFA while their clinical associations remain an immunological enigma. Unlike other ANA, there is a growing body of evidence that anti-DFS70 antibodies, when present in high titers and in isolation (i.e. in the absence of any accompanying autoimmune disease-specific antibodies) are useful to aid in the exclusion of systemic autoimmune rheumatic diseases (SARD), also called ANA-associated rheumatic diseases (AARD). The correlation between the DFS pattern by IFA observed through HEp-2 cells and the presence of anti-DFS70 antibodies detected by enzyme-linked immunosorbent assay (ELISA) has been the subject of increasing interest in autoimmune research. This study provides supporting evidence of the significant association between the DFS pattern by IFA and anti-DFS70 antibodies by ELISA and offers a potential algorithm to triage patients to exclude SARD/AARD.

Methods: 150 positive and 20 negative serum specimens for DFS pattern by HEp-2 cells by IFA, (Sprinter XL/EuroPattern, Euroimmun, NJ), were analyzed for presence of anti-DFS70 antibodies by ELISA (QuantaLyzer 3000, Werfen CA). The agreement of the DFS70 by ELISA was established by direct comparison of results with those generated by an established or reference method HEp-2 cells DFS pattern by IFA.

Results: When compared, samples between DFS pattern by HEp-2 cells IFA and anti-DFS70 antibodies by ELISA yielded an agreement of 97.1% (95% confidence intervals of 93.1-98.7%), McNemar’s Test Chi Square of p >0.999, with a relative sensitivity of 98.0% and a specificity of 90.0%.We propose the following potential algorithm to triage patients with or without SARD/AARD (see figure).

Conclusion: This study demonstrated that accurate reading of DFS pattern by HEp-2 IFA identification provided a significant rate of anti-DFS70 antibodies detected by ELISA. The correlation between the DFS pattern by HEp-2 IFA observed and the presence of anti-DFS70 antibodies detected by ELISA could provide valuable insights into autoimmune diseases. The combined use of these techniques allows for a more comprehensive assessment of autoantibody profiles, aiding in accurate classification, prognosis, and personalized treatment strategies. Further research is needed to elucidate the clinical implications and significance of this anti-DFS antibodies in different conditions.

Supporting image 1


Disclosures: V. ricchiuti: None; M. Nappi: LabCorp, 3; K. Chun: None; A. Grover: None; R. Punzalan: None.

To cite this abstract in AMA style:

ricchiuti V, Nappi M, Chun K, Grover A, Punzalan R. Correlation of Anti-DFS70 Autoantibodies by ELISA with HEp-2 Cells DFS Pattern by IFA [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/correlation-of-anti-dfs70-autoantibodies-by-elisa-with-hep-2-cells-dfs-pattern-by-ifa/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/correlation-of-anti-dfs70-autoantibodies-by-elisa-with-hep-2-cells-dfs-pattern-by-ifa/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology